Bayer SE secures rights to in €310m deal
Under the licence deal, BridgeBio Pharma, Inc. will pass the commercialisation rights for the transthyretin stabiliser acoramidis in Europe where...
Bayer's Ask Bio unit starts Phase II heart failure gene therapy
The Phase II trial called GenePHIT is the largest adaptive, double-blind, placebo-controlled, randomised, multicentre trial ever to evaluate the...
Onera Health raises US$32m in Series C round
Existing investors Innovation Industries, Invest-NL, imec.xpand, BOM, and 15th Rock participated in the financing of Onera Health (Eindhoven) along...
AstraZeneca buys Chinese Gracell Biotechnologies for $1.2bn
Pharmaceutical giant Astrazeneca with CEO Pascal Soriot wants to take over the Chinese company Gracell Biotechnologies in order to strengthen its...
Finnish Enifer Oy secures €12m grant to scale up
The new factory will have a production capacity of around 3 million kilograms a year – equal to the amount of protein from 30,000 cows but with...
GLP1 agonists: FDA investigates suicide risk
It is rare for the US Food and Drug Administration (FDA) to act more slowly than its European counterpart, the EMA. However, this is the case with...
Novo Nordisk to acquire Cardior Pharmaceuticals
The take-over agreement includes Cardior’s lead compound CDR132L, currently in Phase II clinical development for the treatment of heart failure....